Single-use percutaneous catheters for intraperitoneal P32 therapy

Harriet O. Smith, D. E. Gaudette, G. L. Goldberg, David M. Milstein, C. L. DeVictoria, C. D. Runowicz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. Intraperitoneal (IP) radioactive chromic phosphate (P32) remains investigational in the treatment of patients with ovarian and/or endometrial cancer. Single-use percutaneously placed catheters offer the advantage of therapy without additional surgery. Methods. Between August, 1986 and October, 1992, 25 patients underwent bedside percutaneous catheter placement under local anesthesia without ultrasonographic or radiologic guidance, using a specialized central venous catheter. Results. Catheter insertion was successful in 22 of 25 patients (88%) with good IP distribution. Of these, 18 of 22 patients (82%) underwent successful catheter placement with one attempt and 4 of 22 (18%) after one to three additional attempts. The technical failure rate was 12%. Multiple catheter placement attempts were associated with an increased incidence of complications (r = 0.63). Bowel entry occurred in 4 of 25 patients (16%) during 5 of 43 attempts at catheter placement (12%) but was without clinical sequelae. The likelihood of bowel entry significantly increased with more than two attempts (P = 0.02). A median of 39 days (range, 7-156 days) elapsed between the preceding laparotomy and catheter insertion. Conclusions. Percutaneous catheter placement is successful and well tolerated in the majority of patients and should be considered for patients receiving IP P32.

Original languageEnglish (US)
Pages (from-to)2633-2637
Number of pages5
JournalCancer
Volume73
Issue number10
DOIs
StatePublished - 1994

Fingerprint

Catheters
Therapeutics
Investigational Therapies
Central Venous Catheters
Local Anesthesia
Endometrial Neoplasms
Ovarian Neoplasms
Laparotomy
Incidence

Keywords

  • intraperitoneal catheter complications
  • ovarian neoplasm
  • radioactive chromic phosphate (P)
  • uterine neoplasm

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Smith, H. O., Gaudette, D. E., Goldberg, G. L., Milstein, D. M., DeVictoria, C. L., & Runowicz, C. D. (1994). Single-use percutaneous catheters for intraperitoneal P32 therapy. Cancer, 73(10), 2633-2637. https://doi.org/10.1002/1097-0142(19940515)73:10<2633::AID-CNCR2820731027>3.0.CO;2-Z

Single-use percutaneous catheters for intraperitoneal P32 therapy. / Smith, Harriet O.; Gaudette, D. E.; Goldberg, G. L.; Milstein, David M.; DeVictoria, C. L.; Runowicz, C. D.

In: Cancer, Vol. 73, No. 10, 1994, p. 2633-2637.

Research output: Contribution to journalArticle

Smith, HO, Gaudette, DE, Goldberg, GL, Milstein, DM, DeVictoria, CL & Runowicz, CD 1994, 'Single-use percutaneous catheters for intraperitoneal P32 therapy', Cancer, vol. 73, no. 10, pp. 2633-2637. https://doi.org/10.1002/1097-0142(19940515)73:10<2633::AID-CNCR2820731027>3.0.CO;2-Z
Smith HO, Gaudette DE, Goldberg GL, Milstein DM, DeVictoria CL, Runowicz CD. Single-use percutaneous catheters for intraperitoneal P32 therapy. Cancer. 1994;73(10):2633-2637. https://doi.org/10.1002/1097-0142(19940515)73:10<2633::AID-CNCR2820731027>3.0.CO;2-Z
Smith, Harriet O. ; Gaudette, D. E. ; Goldberg, G. L. ; Milstein, David M. ; DeVictoria, C. L. ; Runowicz, C. D. / Single-use percutaneous catheters for intraperitoneal P32 therapy. In: Cancer. 1994 ; Vol. 73, No. 10. pp. 2633-2637.
@article{b814616655504db9b004ec5fba48beb7,
title = "Single-use percutaneous catheters for intraperitoneal P32 therapy",
abstract = "Background. Intraperitoneal (IP) radioactive chromic phosphate (P32) remains investigational in the treatment of patients with ovarian and/or endometrial cancer. Single-use percutaneously placed catheters offer the advantage of therapy without additional surgery. Methods. Between August, 1986 and October, 1992, 25 patients underwent bedside percutaneous catheter placement under local anesthesia without ultrasonographic or radiologic guidance, using a specialized central venous catheter. Results. Catheter insertion was successful in 22 of 25 patients (88{\%}) with good IP distribution. Of these, 18 of 22 patients (82{\%}) underwent successful catheter placement with one attempt and 4 of 22 (18{\%}) after one to three additional attempts. The technical failure rate was 12{\%}. Multiple catheter placement attempts were associated with an increased incidence of complications (r = 0.63). Bowel entry occurred in 4 of 25 patients (16{\%}) during 5 of 43 attempts at catheter placement (12{\%}) but was without clinical sequelae. The likelihood of bowel entry significantly increased with more than two attempts (P = 0.02). A median of 39 days (range, 7-156 days) elapsed between the preceding laparotomy and catheter insertion. Conclusions. Percutaneous catheter placement is successful and well tolerated in the majority of patients and should be considered for patients receiving IP P32.",
keywords = "intraperitoneal catheter complications, ovarian neoplasm, radioactive chromic phosphate (P), uterine neoplasm",
author = "Smith, {Harriet O.} and Gaudette, {D. E.} and Goldberg, {G. L.} and Milstein, {David M.} and DeVictoria, {C. L.} and Runowicz, {C. D.}",
year = "1994",
doi = "10.1002/1097-0142(19940515)73:10<2633::AID-CNCR2820731027>3.0.CO;2-Z",
language = "English (US)",
volume = "73",
pages = "2633--2637",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Single-use percutaneous catheters for intraperitoneal P32 therapy

AU - Smith, Harriet O.

AU - Gaudette, D. E.

AU - Goldberg, G. L.

AU - Milstein, David M.

AU - DeVictoria, C. L.

AU - Runowicz, C. D.

PY - 1994

Y1 - 1994

N2 - Background. Intraperitoneal (IP) radioactive chromic phosphate (P32) remains investigational in the treatment of patients with ovarian and/or endometrial cancer. Single-use percutaneously placed catheters offer the advantage of therapy without additional surgery. Methods. Between August, 1986 and October, 1992, 25 patients underwent bedside percutaneous catheter placement under local anesthesia without ultrasonographic or radiologic guidance, using a specialized central venous catheter. Results. Catheter insertion was successful in 22 of 25 patients (88%) with good IP distribution. Of these, 18 of 22 patients (82%) underwent successful catheter placement with one attempt and 4 of 22 (18%) after one to three additional attempts. The technical failure rate was 12%. Multiple catheter placement attempts were associated with an increased incidence of complications (r = 0.63). Bowel entry occurred in 4 of 25 patients (16%) during 5 of 43 attempts at catheter placement (12%) but was without clinical sequelae. The likelihood of bowel entry significantly increased with more than two attempts (P = 0.02). A median of 39 days (range, 7-156 days) elapsed between the preceding laparotomy and catheter insertion. Conclusions. Percutaneous catheter placement is successful and well tolerated in the majority of patients and should be considered for patients receiving IP P32.

AB - Background. Intraperitoneal (IP) radioactive chromic phosphate (P32) remains investigational in the treatment of patients with ovarian and/or endometrial cancer. Single-use percutaneously placed catheters offer the advantage of therapy without additional surgery. Methods. Between August, 1986 and October, 1992, 25 patients underwent bedside percutaneous catheter placement under local anesthesia without ultrasonographic or radiologic guidance, using a specialized central venous catheter. Results. Catheter insertion was successful in 22 of 25 patients (88%) with good IP distribution. Of these, 18 of 22 patients (82%) underwent successful catheter placement with one attempt and 4 of 22 (18%) after one to three additional attempts. The technical failure rate was 12%. Multiple catheter placement attempts were associated with an increased incidence of complications (r = 0.63). Bowel entry occurred in 4 of 25 patients (16%) during 5 of 43 attempts at catheter placement (12%) but was without clinical sequelae. The likelihood of bowel entry significantly increased with more than two attempts (P = 0.02). A median of 39 days (range, 7-156 days) elapsed between the preceding laparotomy and catheter insertion. Conclusions. Percutaneous catheter placement is successful and well tolerated in the majority of patients and should be considered for patients receiving IP P32.

KW - intraperitoneal catheter complications

KW - ovarian neoplasm

KW - radioactive chromic phosphate (P)

KW - uterine neoplasm

UR - http://www.scopus.com/inward/record.url?scp=0028306840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028306840&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940515)73:10<2633::AID-CNCR2820731027>3.0.CO;2-Z

DO - 10.1002/1097-0142(19940515)73:10<2633::AID-CNCR2820731027>3.0.CO;2-Z

M3 - Article

C2 - 8174063

AN - SCOPUS:0028306840

VL - 73

SP - 2633

EP - 2637

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -